X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) announced that its management team will participate in the Guggenheim Second Annual Healthcare Innovation Conference in Boston on November 10–12, 2025. The company will host a fireside chat on November 10 at 8:30 a.m. ET and will be available for one-on-one investor meetings. A live webcast of the fireside chat will be available on the company’s Investors > Events and Presentations page, with a replay accessible for 30 days after the event. For more information, visit investors.x4pharma.com.
Positive
- None.
Negative
- None.
News Market Reaction 16 Alerts
On the day this news was published, XFOR declined 10.58%, reflecting a significant negative market reaction. Argus tracked a trough of -6.4% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $37M from the company's valuation, bringing the market cap to $314M at that time.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Second Annual Healthcare Innovation Conference on November 10-12, 2025 in Boston.
The X4 team will hold a fireside chat on November 10th at 8:30 a.m. ET and will be available for one-on-one meetings with investors.
A webcast of the fireside chat will be available under the “Events and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.x4pharma.com.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in patients with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
X4 Investor Contact:
IR@X4pharma.com
FAQ
When will X4 Pharmaceuticals (XFOR) present at the Guggenheim Healthcare Innovation Conference?
How can investors watch X4 Pharmaceuticals (XFOR) fireside chat on November 10, 2025?
Will X4 Pharmaceuticals (XFOR) offer a replay of the Guggenheim conference webcast?
Can investors request one-on-one meetings with X4 Pharmaceuticals (XFOR) at the conference?
Where can I find more information about X4 Pharmaceuticals (XFOR) conference participation?
